ClinicalTrials.gg

Program

ENPP1 Inhibitor RBS2418

Its studies are mostly in Colorectal Neoplasms · Carcinoma, Hepatocellular · Neoplasm Metastasis, led by Riboscience, LLC..

Furthest: phase 2, since Jan 30, 20253 company-led studies, 3 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Riboscience, LLC.33 open or runningphase 2since Jan 30, 2025Feb 9, 2022Apr 2027phase 2 · NCT07175441

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 9, 2022First study: phase 1 study in Neoplasm MetastasisFirst studyNCT05270213 · 164 planned · United States
  2. Jan 30, 2025Phase 2 study in Colorectal NeoplasmsNCT06824064 · 150 planned · United States, Puerto Rico, Vietnam
  3. Sep 9, 2025Phase 2 study in Advanced Unresectable Hepatocellular CarcinomaNCT07175441 · 220 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 2 study in Advanced Unresectable Hepatocellular CarcinomaNCT07175441
  2. Apr 2027Primary completion: phase 1 study in Neoplasm MetastasisNCT05270213
  3. Dec 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT06824064

TargetBeta

ENPP1 →read by rule
“A selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), ”NCIt, by rule

Other programs on ENPP1

ProgramCompanyFurthest phaseStudies
TXN10128ruletxinno-bioscience-incphase 22

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07175441Advanced Unresectable Hepatocellular Carcinoma · United States2RecruitingApr 2027220
NCT06824064Colorectal Neoplasms · United States, Puerto Rico, Vietnam2RecruitingDec 2027150
NCT05270213Neoplasm Metastasis · United States1RecruitingApr 2027164

How it is read

Names in the registry

  • “RBS2418”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.